Indian medical-device maker spanning infusion, renal, cardiology and orthopaedics; sold in 125+ countries.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 44 | 48 | 48 | 48 | 48 | 51 | 51 | 51 |
| Reserves | 385 | 906 | 1.0k | 1.2k | 1.4k | 2.7k | 2.9k | 3.0k |
| Borrowings | 194 | 126 | 111 | 137 | 164 | 172 | 240 | 252 |
| Other Liabilities | 117 | 107 | 146 | 167 | 199 | 224 | 429 | 246 |
| Total Liabilities | 740 | 1.2k | 1.3k | 1.5k | 1.8k | 3.1k | 3.6k | 3.5k |
| AssetsFixed Assets | 328 | 389 | 451 | 598 | 831 | 1.0k | 1.4k | 1.2k |
| CWIP | 25 | 21 | 43 | 78 | 71 | 93 | 83 | 90 |
| Investments | 58 | 385 | 384 | 181 | 221 | 1.1k | 930 | 1.2k |
| Other Assets | 330 | 392 | 456 | 681 | 699 | 873 | 1.1k | 994 |
| Total Assets | 740 | 1.2k | 1.3k | 1.5k | 1.8k | 3.1k | 3.6k | 3.5k |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 113 | 127 | 116 | 126 | 197 | 256 | 237 | 245 |
| Cash from Investing | -104 | -106 | -434 | -89 | -189 | -237 | -1.2k | -268 |
| Cash from Financing | -10 | -22 | 319 | -40 | -8 | -17 | 953 | 28 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 68 | 23 | 23 | -24 | -40 | -13 | -87 | -49 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (59.9×) and current (47.2×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 23.6% growth and a 47× exit, ₹1563 only delivers your return if you pay ₹2,056. The price is currently baking in 18% growth.
EPS grows 23.6%/yr for 5 years, then fades to 6% over 2, exits at 47×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 23.6% | 40.97 |
| FY28 | 23.6% | 50.64 |
| FY29 | 23.6% | 62.59 |
| FY30 | 23.6% | 77.37 |
| FY31 | 23.6% | 95.63 |
| FY32 | 14.8% ·fade | 109.78 |
| FY33 | 6.0% ·fade | 116.37 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.